Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13452774 | 1.00 | KMT2A (0.39) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12572936 | 1.00 | KMT2A (0.39) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15786185 | 0.98 | KMT2A (0.41) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21398646 | 0.98 | KMT2A (0.41) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23371066 | 0.98 | KMT2A (0.41) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL11997996 | 0.93 | CHRM3 (0.35) | KMT2AHTTCHRM3 | |
| SCHEMBL58010 | 0.93 | CHRM3 (0.35) | KMT2AHTTCHRM3 | |
| SCHEMBL463540 | 0.93 | CHRM3 (0.35) | KMT2AHTTCHRM3 | |
| SCHEMBL17835201 | 0.84 | — | — | |
| SCHEMBL18269015 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021158899-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-12 | — | — | WO | disclosed |
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | CDK3, CDK1, CDK14 | KMT2A 3014/4885PSEN1 755/4885PSEN2 531/4885 |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | KMT2A 2786/4885PSEN1 533/4885PSEN2 570/4885 |
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | EEF1A1, EEF1B2, EEF1G | KMT2A 3519/4885PSEN1 3905/4885PSEN2 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.